Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Work In Process: 2022-2024

Historic Work In Process for Gyre Therapeutics (GYRE) over the last 3 years, with Dec 2024 value amounting to $2.9 million.

  • Gyre Therapeutics' Work In Process rose 25.36% to $4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.4 million, marking a year-over-year increase of 25.36%. This contributed to the annual value of $2.9 million for FY2024, which is 46.67% up from last year.
  • As of FY2024, Gyre Therapeutics' Work In Process stood at $2.9 million, which was up 46.67% from $2.0 million recorded in FY2023.
  • In the past 5 years, Gyre Therapeutics' Work In Process ranged from a high of $3.7 million in FY2022 and a low of $2.0 million during FY2023.
  • Moreover, its 3-year median value for Work In Process was $2.9 million (2024), whereas its average is $2.9 million.
  • As far as peak fluctuations go, Gyre Therapeutics' Work In Process crashed by 45.54% in 2023, and later skyrocketed by 46.67% in 2024.
  • Over the past 3 years, Gyre Therapeutics' Work In Process (Yearly) stood at $3.7 million in 2022, then crashed by 45.54% to $2.0 million in 2023, then soared by 46.67% to $2.9 million in 2024.